These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 28511645)

  • 41. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3.
    Liu X; Wang Q; Yang G; Marando C; Koblish HK; Hall LM; Fridman JS; Behshad E; Wynn R; Li Y; Boer J; Diamond S; He C; Xu M; Zhuo J; Yao W; Newton RC; Scherle PA
    Clin Cancer Res; 2011 Nov; 17(22):7127-38. PubMed ID: 21918175
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma.
    Ranieri G; Mammì M; Donato Di Paola E; Russo E; Gallelli L; Citraro R; Gadaleta CD; Marech I; Ammendola M; De Sarro G
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):322-9. PubMed ID: 24041629
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adaptor protein Crk induces Src-dependent activation of p38 MAPK in regulation of synovial sarcoma cell proliferation.
    Watanabe T; Tsuda M; Tanaka S; Ohba Y; Kawaguchi H; Majima T; Sawa H; Minami A
    Mol Cancer Res; 2009 Sep; 7(9):1582-92. PubMed ID: 19737974
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Lung Fibrosis in Mice.
    Koyama K; Goto H; Morizumi S; Kagawa K; Nishimura H; Sato S; Kawano H; Toyoda Y; Ogawa H; Homma S; Nishioka Y
    Am J Respir Cell Mol Biol; 2019 Apr; 60(4):478-487. PubMed ID: 30540913
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-tumor activity of oridonin on SNU-5 subcutaneous xenograft model via regulation of c-Met pathway.
    Liu H; Qian C; Shen Z
    Tumour Biol; 2014 Sep; 35(9):9139-46. PubMed ID: 24916572
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
    Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
    Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma.
    Govaere O; Petz M; Wouters J; Vandewynckel YP; Scott EJ; Topal B; Nevens F; Verslype C; Anstee QM; Van Vlierberghe H; Mikulits W; Roskams T
    Oncogene; 2017 Nov; 36(47):6605-6616. PubMed ID: 28783171
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis.
    Campbell JS; Johnson MM; Bauer RL; Hudkins KL; Gilbertson DG; Riehle KJ; Yeh MM; Alpers CE; Fausto N
    Differentiation; 2007 Nov; 75(9):843-52. PubMed ID: 17999742
    [TBL] [Abstract][Full Text] [Related]  

  • 50. c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma.
    Kim HJ; Yoon A; Ryu JY; Cho YJ; Choi JJ; Song SY; Bang H; Lee JS; Cho WC; Choi CH; Lee JW; Kim BG; Bae DS
    Sci Rep; 2016 Dec; 6():38502. PubMed ID: 27917934
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phosphatidylinositol-3'-kinase/AKT signaling is essential in synovial sarcoma.
    Friedrichs N; Trautmann M; Endl E; Sievers E; Kindler D; Wurst P; Czerwitzki J; Steiner S; Renner M; Penzel R; Koch A; Larsson O; Tanaka S; Kawai A; Schirmacher P; Mechtersheimer G; Wardelmann E; Buettner R; Hartmann W
    Int J Cancer; 2011 Oct; 129(7):1564-75. PubMed ID: 21128248
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.
    Munshi N; Jeay S; Li Y; Chen CR; France DS; Ashwell MA; Hill J; Moussa MM; Leggett DS; Li CJ
    Mol Cancer Ther; 2010 Jun; 9(6):1544-53. PubMed ID: 20484018
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy.
    Kim JS; Kim MY; Hong S
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892160
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target.
    Loizos N; Xu Y; Huber J; Liu M; Lu D; Finnerty B; Rolser R; Malikzay A; Persaud A; Corcoran E; Deevi DS; Balderes P; Bassi R; Jimenez X; Joynes CJ; Mangalampalli VR; Steiner P; Tonra JR; Wu Y; Pereira DS; Zhu Z; Ludwig DL; Hicklin DJ; Bohlen P; Witte L; Kussie P
    Mol Cancer Ther; 2005 Mar; 4(3):369-79. PubMed ID: 15767546
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
    Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
    Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Platelet-derived growth factor receptor alpha (PDGFRα) is overexpressed in NK/T-cell lymphoma and mediates cell survival.
    Lu L; Fu X; Li Z; Qiu Y; Li W; Zhou Z; Xue W; Wang Y; Jin M; Zhang M
    Biochem Biophys Res Commun; 2018 Oct; 504(2):525-531. PubMed ID: 30201265
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mutational analysis of the c-KIT AND PDGFRalpha in a series of molecularly well-characterized synovial sarcomas.
    López-Guerrero JA; Navarro S; Noguera R; Carda C; Fariñas SC; Pellín A; Llombart-Bosch A
    Diagn Mol Pathol; 2005 Sep; 14(3):134-9. PubMed ID: 16106193
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
    Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW
    Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942
    [TBL] [Abstract][Full Text] [Related]  

  • 60. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.
    Bladt F; Faden B; Friese-Hamim M; Knuehl C; Wilm C; Fittschen C; Grädler U; Meyring M; Dorsch D; Jaehrling F; Pehl U; Stieber F; Schadt O; Blaukat A
    Clin Cancer Res; 2013 Jun; 19(11):2941-51. PubMed ID: 23553846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.